These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16093841)

  • 21. Interleukin-6 in rheumatoid arthritis.
    Nishimoto N
    Curr Opin Rheumatol; 2006 May; 18(3):277-81. PubMed ID: 16582692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anakinra treatment in refractory systemic onset juvenile arthritis].
    Garrido Colino C; Saavedra Lozano J
    An Pediatr (Barc); 2008 Mar; 68(3):305-6. PubMed ID: 18358148
    [No Abstract]   [Full Text] [Related]  

  • 23. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Juvenile Idiopathic Arthritis.
    Barut K; Adrovic A; Şahin S; Kasapçopur Ö
    Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)].
    Horneff G
    Z Rheumatol; 2005 Jun; 64(5):317-26. PubMed ID: 15965816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis.
    Kessel C; Lippitz K; Weinhage T; Hinze C; Wittkowski H; Holzinger D; Fall N; Grom AA; Gruen N; Foell D
    Arthritis Rheumatol; 2017 Jul; 69(7):1480-1494. PubMed ID: 28296284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
    Baris HE; Anderson E; Sozeri B; Dedeoglu F
    Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Juvenile rheumatoid arthritis.
    Schneider R; Passo MH
    Rheum Dis Clin North Am; 2002 Aug; 28(3):503-30. PubMed ID: 12380368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis.
    Uettwiller F; Perlbarg J; Pinto G; Bader-Meunier B; Mouy R; Compeyrot-Lacassagne S; Melki I; Wouters C; Prieur AM; Landais P; Polak M; Quartier P
    J Rheumatol; 2014 Jan; 41(1):128-35. PubMed ID: 24293576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Juvenile rheumatoid arthritis: therapeutic perspectives.
    Chikanza IC
    Paediatr Drugs; 2002; 4(5):335-48. PubMed ID: 11994038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-6 blockers in systemic onset juvenile idiopathic arthritis.
    Barone P; Pignataro R; Garozzo MT; Leonardi S
    Immunotherapy; 2016; 8(1):79-87. PubMed ID: 26642378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunopathogenesis of juvenile rheumatoid arthritis.
    Moore TL
    Curr Opin Rheumatol; 1999 Sep; 11(5):377-83. PubMed ID: 10503658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
    Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
    J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
    Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
    Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [BIOLOGIC THERAPY FOR JUVENILE IDIOPATHIC ARTHRITIS].
    Brik R
    Harefuah; 2017 Oct; 156(10):659-662. PubMed ID: 29072387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Juvenile rheumatoid arthritis.
    Schaller JG
    Pediatr Rev; 1997 Oct; 18(10):337-49. PubMed ID: 9311247
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
    Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.